EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Platelet-Rich Plasma Versus Injectable Platelet-Rich Fibrin in the Management of Temporomandibular Joint Osteoarthritis: A Narrative Review

Tânia Martins, Bruno Daniel Carneiro, Carlos Silva Faria, Daniel Humberto Pozza

Biologics · 21.05.2026 · 6 (2) · 16

DOI: 10.3390/biologics6020016 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biologics, online erschienen am 21.05.2026. Verfasst von Tânia Martins und 3 weiteren Autor:innen. Die Arbeit nennt 172 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Temporomandibular joint osteoarthritis (TMJ-OA) is a multifactorial degenerative disorder characterized by progressive cartilage degradation, subchondral bone remodeling, and chronic inflammation, leading to pain and functional impairment in affected individuals. Despite its clinical impact, effective disease-modifying treatments remain limited, highlighting the need for innovative therapeutic approaches for treating this condition in the future. This manuscript examines the biological rationale, clinical applications, and therapeutic potential of platelet-rich plasma (PRP) and injectable platelet-rich fibrin (i-PRF) in the management of TMJ-OA. As autologous platelet-derived biomaterials, PRP and i-PRF contain high concentrations of growth factors and bioactive molecules that can modulate inflammatory responses and support tissue repair. PRP is associated with a relatively rapid release of these mediators, whereas i-PRF forms a fibrin matrix that may enable a more sustained release profile. Current clinical evidence suggests that both therapies show potential to contribute to pain reduction and may facilitate improvements in mandibular function. However, substantial heterogeneity in preparation protocols, study designs, and outcome measures limits the comparability and generalizability of these findings to the general population. Overall, PRP and i-PRF represent promising, minimally invasive regenerative strategies for managing TMJ-OA.

Zitieren

APA

Martins, T., Carneiro, B. D., Faria, C. S., & Pozza, D. H. (2026). Platelet-Rich Plasma Versus Injectable Platelet-Rich Fibrin in the Management of Temporomandibular Joint Osteoarthritis: A Narrative Review. Biologics, 6(2), 16. https://doi.org/10.3390/biologics6020016

Vancouver

Martins T, Carneiro BD, Faria CS, Pozza DH. Platelet-Rich Plasma Versus Injectable Platelet-Rich Fibrin in the Management of Temporomandibular Joint Osteoarthritis: A Narrative Review. Biologics. 2026;6(2):16. doi:10.3390/biologics6020016

BibTeX
@article{Martins2026,
  author = {Martins, Tânia and Carneiro, Bruno Daniel and Faria, Carlos Silva and Pozza, Daniel Humberto},
  title = {Platelet-Rich Plasma Versus Injectable Platelet-Rich Fibrin in the Management of Temporomandibular Joint Osteoarthritis: A Narrative Review},
  journal = {Biologics},
  year = {2026},
  volume = {6},
  number = {2},
  pages = {16},
  doi = {10.3390/biologics6020016}
}
Kostenlos starten →